Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L

被引:0
作者
Mix, Kalie [1 ]
Sun, Tingwan [1 ,2 ]
Hall, Brian [1 ]
Newton, Jocelyn [1 ,3 ]
Eng, Christina [1 ]
Guo, Yongjing [1 ]
Reczek, David [1 ]
机构
[1] Sanofi US Large Mol Res, 350 Water St, Cambridge, MA 02141 USA
[2] Cambridge Antibody Labs, LLC, Framingham, MA USA
[3] Sanofi Vaccines, Cambridge, MA USA
关键词
Bispecific antibodies; CODV; multi-specific antibodies; protein purification; trispecific antibodies;
D O I
10.1080/19420862.2025.2483272
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Multispecific antibodies (msAbs) are becoming more prevalent as formats of choice for therapeutic antibody development due to their ability to modulate multiple biological targets. However, msAbs present unique protein production challenges due to product-related impurities, which are difficult to remove without loss of the protein of interest. Here, we report a versatile approach to remove product-related impurities by altering the binding affinity of light chains to Kappa Select (KS) or Protein L (Pro-L) resins. Introduction of amino acid mutations in the constant light chain domain or Framework 1 of the light chain abolished binding to KS and Pro-L resins, respectively, while antigen binding affinity remained intact. These purification-enabling mutations (PEMs) did not affect the thermal stability or purity of the proteins tested. In conjunction with PEMs, we demonstrate the design and application of an entirely affinity-based purification scheme employing Protein A (Pro-A), followed by KS and Pro-L affinity resins, to remove light chain mispaired species in Y-shaped bispecific antibodies and crossover dual variable domain (CODV) tri-specific antibodies. In principle, this purification scheme could be applied to any IgG-like msAb since it is compatible with Fc knobs-into-holes mutations and Fab arm charge-pair mutations. Moreover, it should be adaptable across a range of production scales and medium to high-throughput purification workflows within early-stage research.
引用
收藏
页数:12
相关论文
共 19 条
[1]   Novel CH1:CL interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies [J].
Boenisch, Maximilian ;
Sellmann, Carolin ;
Maresch, Daniel ;
Halbig, Claudia ;
Becker, Stefan ;
Toleikis, Lars ;
Hock, Bjoern ;
Rueker, Florian .
PROTEIN ENGINEERING DESIGN & SELECTION, 2017, 30 (09) :685-696
[2]   Controlled conductivity at low pH in Protein L chromatography enables separation of bispecific and other antibody formats by their binding valency [J].
Chen, Chen ;
Wakabayashi, Tetsuya ;
Muraoka, Masaru ;
Shu, Feng ;
Shan, Chia Wei ;
Kun, Chong Chor ;
Jang, Ching Tim ;
Soehano, Ishin ;
Shimizu, Yuichiro ;
Igawa, Tomoyuki ;
Nezu, Jun-Ichi .
MABS, 2019, 11 (04) :632-638
[3]   Structural Basis of Enhanced Crystallizability Induced by a Molecular Chaperone for Antibody Antigen-Binding Fragments [J].
Ereno-Orbea, June ;
Sicard, Taylor ;
Cui, Hong ;
Carson, Jacob ;
Hermans, Pim ;
Julien, Jean-Philippe .
JOURNAL OF MOLECULAR BIOLOGY, 2018, 430 (03) :322-336
[4]   Evidence for plasticity and structural mimicry at the immunoglobulin light chain-protein L interface [J].
Graille, M ;
Harrison, S ;
Crump, MP ;
Findlow, SC ;
Housden, NG ;
Muller, BH ;
Battail-Poirot, N ;
Sibai, G ;
Sutton, BJ ;
Taussig, MJ ;
Jolivet-Reynaud, C ;
Gore, MG ;
Stura, EA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (49) :47500-47506
[5]   Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs [J].
Haslam, Alyson ;
Prasad, Vinay .
JAMA NETWORK OPEN, 2019, 2 (05)
[6]   Antibodies to watch in 2022 [J].
Kaplon, Helene ;
Chenoweth, Alicia ;
Crescioli, Silvia ;
Reichert, Janice M. .
MABS, 2022, 14 (01)
[7]   Engineering IgG-Like Bispecific AntibodiesAn Overview [J].
Krah, Simon ;
Kolmar, Harald ;
Becker, Stefan ;
Zielonka, Stefan .
ANTIBODIES, 2018, 7 (03)
[8]   Bispecific antibodies: a mechanistic review of the pipeline [J].
Labrijn, Aran F. ;
Janmaat, Maarten L. ;
Reichert, Janice M. ;
Parren, Paul W. H. I. .
NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (08) :585-608
[9]   FDA approves 100th monoclonal antibody product [J].
Mullard, Asher .
NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (07) :491-495
[10]   High-Throughput Generation of Bipod (Fab x scFv) Bispecific Antibodies Exploits Differential Chain Expression and Affinity Capture [J].
Nesspor, Thomas C. ;
Kinealy, Kyle ;
Mazzanti, Nicholas ;
Diem, Michael D. ;
Boye, Kevin ;
Hoffman, Hunter ;
Springer, Christine ;
Sprenkle, Justin ;
Powers, Gordon ;
Jiang, Haiyan ;
La Porte, Sherry L. ;
Ganesan, Rajkumar ;
Singh, Sanjaya ;
Zwolak, Adam .
SCIENTIFIC REPORTS, 2020, 10 (01)